1621/1816US=55 / Biol/Mol
Meier C, Balzarini J, Meerbach A. The cycloSal-nucleotide delivery system: development of chemical trojan horses as antiviral agents. In: Peters GJ. Deoxynucleoside analogs in cancer therapy. New Jersey: Humana Press, 2006. p. 353-401. (Cancer Drug Discovery and Development) ISBN 978-1-58829-327-5.

SISTEMA DE ENTREGA; CICLOSAL DE NUCLEOTIDEO; AGENTES ANTIVIRAIS


1622/1816US=55 / Biol/Mol
Gojkovic Z, Karlsson A. Purine and pyrimidine-based analogs and suicide gene therapy. In: Peters GJ. Deoxynucleoside analogs in cancer therapy. New Jersey: Humana Press, 2006. p. 403-39. (Cancer Drug Discovery and Development) ISBN 978-1-58829-327-5.

PURINA; ANALOGOS DE PIRIMIDINA-BASE; TERAPIA DE GENE SUICIDA; ACICLOVIR; CITOSINA DESAMINASE; DESOXINUCLEOSIDO QUINASE; SISTEMA DE ENTREGA DE DROGA; FLUOROCITOSINE; GANCICLOVIR; TERAPIA GENICA; TIMIDINA QUINASE DO HERPES; GENES SUICIDAS; TIMIDINA QUINASE


1623/1816US=55 / Biol/Mol
Direcks WGE, Lammertsma AA, Molthoff CFM. 3-deoxy-3-fluorothymidine as a tracer of proliferation in positron emission tomographyPurine and pyrimidine-based analogs and suicide gene therapy. In: Peters GJ. Deoxynucleoside analogs in cancer therapy. New Jersey: Humana Press, 2006. p. 441-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-327-5.

3-DESOXI-3-FLUOROTIMIDINA; MARCADOR DE PROLIFERACAO; TOMOGRAFIA POR EMISSAO DE POSITRONS


1624/1816US=59 / Enfermagem
Goldstein ML, Byrnes-Casey M, Collins JJ. Pediatric palliative care: pediatric pain: knowing the child before you. In: Ferrell BR, Coyle N. Textbook of palliative nursing. Oxford: University Press, 2006. p. 991-1008. ISBN 978-0-19-51549-3.

PEDIATRICA. CUIDADOS PALIATIVOS; DOR PEDIATRICA; DOR NEUROPATICA; QUEIMADURAS; CANCER; INFECCAO POR VIRUS DA IMUNODEFICIENCIA HUMANA; DOENCA DAS CELULAS SICKEL; ARTRITE CRONICA JUVENIL; FIBROSE CISTICA


1625/1816US=61 / Biol/Mol
Spalding SM, Angel SO, Amendoeira MRR. Toxoplasmose. In: Rossetti ML, Silva CMD, Rodrigues JJS. Doenças infecciosas diagnóstico molecular. Rio de Janeiro: Guanabara-Koogan, 2006. p. 102-111. ISBN 85-2771083-8.

TOXOPLASMOSE HUMANA; TOXOPLASMA GONDII; TRANSMISSAO DA TOXOPLASMOSE; DIAGNOSTICO MOLECULAR


1626/1816US=61 / Câncer
Dewhirst MW, Cao Y, Moeller B, Li CY. Physiological resistance: the cycle between angiogenesis perfusion, and hypoxia in tumors. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 1-19. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

ANGIOGENESE; PERFUSAO; HIPOXIA; VASCULATURA; DIFUSAO


1627/1816US=61 / Câncer
Song CW, Griffin R, Park HJ. Physiological resistance: influence of tumor pH on therapeutic response. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 21-42. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

INTRATUMOR PH; PH EXTRACELULAR; PH INTRACELULAR; INTRATUMORAL MECANISMO DE CONTROLO DE PH; QUIMIOTERAPIA; RADIOTERAPIA; HIPERTERMIA


1628/1816US=61 / Câncer
Lunt SJ, Hill RP. Physiological resistance: tumor oxygenation and treatment response. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 43-66. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

HIPOXIA TUMOR; HIF-1; MARCADORES DE HIPOXIA; DROGAS BIORREDUTIVA; DIRIGIDO GENE-ENZIMA PRO-DROGA TERAPEUTICA


1629/1816US=61 / Câncer
Rak JW, Coomber B, Yu JL. Physiological resistance: oncogenes and tumor suppressor genes in therapeutic resistance. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 67-103. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

ONCOGENES; GENES SUPRESSORES DE TUMORES; RESISTENCIA AS DROGAS; MICROAMBIENTE; INTERACOES TUMOR-HOSPEDEIRO


1630/1816US=61 / Câncer
Mankoff DA, Krohn KA. Physiological resistance: PET imaging of response and resistance to cancer therapy. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 105-22. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

CANCER DE IMAGENS; PET; RESPOSTA; RESISTENCIA; IMAGIOLOGIA MOLECULAR


1631/1816US=61 / Câncer
Mantle I, Dontu G, Liu S, Wicha MS. Biological resistance: cancer stem cells. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 125-36. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

QUIMIOTERAPIA CITOTOXICA; DESREGULACAO; HETEROGENEIDADE TUMOR; TUMOR DE CELULAS ESTAMINAIS; MODELO DE TUMOR DE CELULAS-TRONCO


1632/1816US=61 / Câncer
Waud WR. Biological resistance: therapeutic resistance in leukemia. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 137-50. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

LEUCEMIA P388; LINHAS TUMORAIS RESISTENTES A DROGAS; RESISTENCIA AS DROGAS; RESISTENCIA TERAPEUTICA


1633/1816US=61 / Câncer
Arjona AA, Alvarez E. Biological resistance: tumor site implantation and animal model selection in oncology. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 151-9. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

LOCAL DO TUMOR; IMPLANTACAO SUBCUTANEA; TUMORES INTRADERMICOS; ANGIOGENESE; HIPOXIA


1634/1816US=61 / Câncer
Teicher BA. Biological resistance: in vivo resistance. In: ___. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 161-79. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

RESISTENCIA A CISPLATINA; RESISTENCIA CICLOFOSFAMIDA; EMT-6 CARCINOMA MAMARIO; RESISTENCIA IN VIVO; FATOR DE CRESCIMENTO TRANSFORMANTE-B


1635/1816US=61 / Câncer
Melnikova VO, Bar-Eli M. Biological resistance: characteristics of the metastatic phenotype. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 181-200. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

MELANOMA; METASTASE; ANGIOGENESE; REGULACAO TRANSCRICIONAL; AP-2; CREB


1636/1816US=61 / Câncer
Morin PJ. Biological resistance: the microenvironment and drug resistance. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 201-10. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

MICROAMBIENTE; MATRIZ EXTRACELULAR; CITOCINAS; FACTORES DE CRESCIMENTO; RESISTENCIA AS DROGAS; APOPTOSE; ANOIKIS


1637/1816US=61 / Câncer
Findlay VJ, Townsed DM, Tew KD. Biochemical resistance: glutathione S-transferases in drug resistance. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 213-21. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

GLUTATIONA; GLUTATIONA-S-TRANSFERASE; RESISTENCIA AS DROGAS; CANCER; MAPK; CAMINHO


1638/1816US=61 / Câncer
Notta F, Koropatnick DJ. Biochemical resistance: metallothioneins in drug resistance. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 223-39. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

METALOTIONEINAS; GLUTATIONA; CISPLATINA; VARREDORES DE RADICAIS LIVRES; SULFIDRILOS PROTEINA


1639/1816US=61 / Câncer
Monti E. Biochemical resistance: molecular determinants of intrinsic multidrug resistance in cancer cells and tumors. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 241-60. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

APOPTOSE; RESISTENCIA INTRINSECA; LRP; MRP; P-GLICOPROTEINA


1640/1816US=61 / Câncer
Bates SE, Deeken J, Fan C, Robey RW. Biochemical resistance: new and revised concepts in multidrug resistance. In: Teicher BA. Cancer drug resistance. New Jersey: Humana Press, 2006. p. 261-82. (Cancer Drug Discovery and Development) ISBN 978-1-58829-530-1.

MULTIRRESISTENCIA; SNPS; GP170; SETAMIBI; MULTIRRESISTENCIA; DERIVAM DE CELULAS


Primeira | Anterior | Próxima | Última